
ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims
Investors are lining up to join a securities fraud class action against ADMA Biologics following allegations that the company artificially inflated its stock price. The lawsuit, filed in the wake of a scathing short-seller report, claims the firm misled shareholders regarding its financial health and distribution practices between 2024 and 2026.























